News

Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...

Exploring the barriers and facilitators of immigrants with disabilities accessing health care in the US and Canada, this qualitative meta-synthesis reveals the structural and cultural obstacles faced by this marginalized population and calls...

Artificial intelligence (AI) is rapidly transforming the landscape of early gastric cancer (EGC) detection and treatment, offering promising solutions to improve diagnostic accuracy, treatment planning, and patient outcomes, according to an...

Fedratinib, an oral JAK2 inhibitor, has demonstrated efficacy in treating myelofibrosis (MF), particularly in patients who have failed ruxolitinib therapy, according to a study published in the Blood Cancer Journal.

Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...

A recent study published in Cancers explores the potential of artificial intelligence (AI) to enhance the preliminary staging of non-small cell lung cancer (NSCLC) using computed tomography (CT) imaging.

A recent study published in Gastro Hep Advances evaluated the cost-effectiveness of using serum pepsinogen (PG) screening for the early detection of gastric cancer (GC) in the US.

Patients with disabilities face significant barriers to cancer screening, including communication challenges, physical inaccessibility, financial constraints, and provider assumptions, highlighting the need for targeted interventions to...

A machine learning-driven study analyzing genomic data from patients with non-small cell lung cancer (NSCLC) reveals specific mutations and pathways that influence resistance to checkpoint inhibitor immunotherapy, offering potential targets...

Pre-transplant use of ruxolitinib may enhance survival outcomes for patients with myelofibrosis undergoing stem cell transplantation.